Currently out of the existing stock ratings of Jason Mills, 166 are a BUY (85.13%), 27 are a HOLD (13.85%), 2 are a SELL (1.03%).

Jason Mills

Work Performance Price Targets & Ratings Chart

Analyst Jason Mills, currently employed at CANACCORD, carries an average stock price target met ratio of 84.42% that have a potential upside of 20.63% achieved within 240 days.

Jason Mills’s has documented 387 price targets and ratings displayed on 22 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on PEN, Penumbra at 20-Jan-2026.

Wall Street Analyst Jason Mills

Analyst best performing recommendations are on ELGX (ENDOLOGIX).
The best stock recommendation documented was for VAPO (VAPOTHERM) at 3/5/2020. The price target of $112 was fulfilled within 11 days with a profit of $30.8 (37.93%) receiving and performance score of 34.48.

Average potential price target upside

of $46.43 (32.37%) on VAPO (VAPOTHERM).
of $29.25 (16.77%) on PEN (PENUMBRA).
of $24.28 (33.89%) on NVRO (NEVRO CORP).

BSX Boston Scientific Corp EW Edwards Lifesciences Corp IRT Independence Realty Trust ISRG Intuitive Surgical LMAT LeMaitre Vascular NVRO Nevro Corp STAA STAAR Surgical Company PEN Penumbra TCMD Tactile Systems Technology LIVN LivaNova PLC VAPO Vapotherm AORT Artivion CRY CryoLife SWAV Shockwave Medical MMSI Merit Medical Systems ANGO AngioDynamics ATRC AtriCure NVCN Neovasc STIM Neuronetics TEF Telefonica SA ADR TMDX TransMedics Group ELGX Endologix

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Joanne Wuensch (CITI)